A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer
NCT03197935
Completed
This is a global Phase III, double-blind, randomized, placebo-controlled study designed to evaluate the efficacy and safety of neoadjuvant treatment with atezolizumab (anti-programmed death-ligand 1 \[anti-PD-L1\] antibody) and nab-paclitaxel followed by doxorubicin and cyclophosphamide (nab-pac-AC), or placebo and nab-pac-AC in participants eligible for surgery with initial clinically assessed triple-negative breast cancer (TNBC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/23/2023
Locations: Stanford University Medical Center, Palo Alto, California +67 locations
Conditions: Triple-negative Breast Cancer
Register for Updates
Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02272790
Completed
Adavosertib in combination with carboplatin, paclitaxel, gemcitabine, or PLD.
Gender:
FEMALE
Ages:
Between 18 years and 130 years
Trial Updated:
10/02/2023
Locations: Research Site, Gilbert, Arizona +19 locations
Conditions: Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
Register for Updates
AZD2171 + Chemotherapy in Advanced NSCLC, Colorectal Cancer, or Other Cancer Suitable for Treatment With Capecitabine (Non-Small Lung Cancer Patients Closed to Enrollment as 8/9/07)
NCT00107250
Completed
RATIONALE: AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as paclitaxel, carboplatin, or capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving AZD2171 together with chemotherapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of AZD2171... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
08/03/2023
Locations: Ottawa Hospital Regional Cancer Centre - General Campus, Ottawa, Ontario +1 locations
Conditions: Colorectal Cancer, Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates
Paclitaxel + Carboplatin With/Out Cediranib Maleate in Stage III or Stage IV Non-Small Cell Lung Cancer
NCT00245154
Completed
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving paclitaxel and carboplatin together with AZD2171 may kill more tumor cells. It is not yet known whether giving paclitaxel and carboplatin together w... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
08/03/2023
Locations: Instituto Alexander Fleming, Buenos Aires, Not set +19 locations
Conditions: Lung Cancer
Register for Updates
Cediranib, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00795340
Completed
RATIONALE: Cediranib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether cediranib is more effective than a placebo when given together with paclitaxel and carboplatin in treating patients with non-small cell lung cancer. PURPOSE: This randomized... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/03/2023
Locations: Instituto Nacional de Cancer (INCA), Rio de Janeiro, Not set +18 locations
Conditions: Lung Cancer
Register for Updates
Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer
NCT00993655
Completed
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, carboplatin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving them in different ways may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective in treating patients with ovarian epithelial cancer, primary peritoneal cancer, and fallopian tube ca... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/03/2023
Locations: Mercy-Springfield, Springfield, Missouri +49 locations
Conditions: Fallopian Tube Cancer, Metastatic Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Register for Updates
A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer
NCT01656538
Completed
Researchers doing this study want to evaluate the side effects of Reolysin when given together with paclitaxel. As these drugs have not been given together before, 6-9 patients will be treated with paclitaxel plus reolysin to ensure that side effects are tolerable.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/03/2023
Locations: BCCA - Cancer Centre for the Southern Interior, Kelowna, British Columbia +6 locations
Conditions: Metastatic Breast Cancer
Register for Updates
Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC
NCT01783197
Completed
This research is being done because further research on selumetinib in combination with standard chemotherapy treatment is needed. Although the number of treatment options for patients with advanced non-small cell lung cancer has increased over the past decade, prognosis remains poor, and there is a need for additional therapeutic options.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/03/2023
Locations: BCCA - Vancouver Cancer Centre, Vancouver, British Columbia +3 locations
Conditions: Non Small Cell Lung Cancer
Register for Updates
Nab-Paclitaxel to Paclitaxel in Advanced Urothelial Cancer Progressing on or After Platinum Containing Regimen.
NCT02033993
Completed
The purpose of this study is to compare the effects on urothelial cancer of nab-paclitaxel compared to paclitaxel to treat this disease. This research is being done because currently there is no effective treatment for urothelial cancer that has progressed after prior chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/03/2023
Locations: Townsville Hospital, Douglas, Queensland +36 locations
Conditions: Urothelial Cancer
Register for Updates
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors
NCT03184870
Completed
The purpose of this study is to evaluate the safety profile, tolerability, drug levels, drug effects, and preliminary efficacy of BMS-813160 alone or in combination with either chemotherapy or nivolumab or chemotherapy plus nivolumab in participants with metastatic colorectal and pancreatic cancers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2023
Locations: Local Institution - 0003, Birmingham, Alabama +39 locations
Conditions: Colorectal Cancer, Pancreatic Cancer
Register for Updates
Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
NCT00028990
Completed
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. It is not yet known whether paclitaxel works better with or without bevacizumab in treating breast cancer. PURPOSE: Th... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/14/2023
Locations: MBCCOP - Gulf Coast, Mobile, Alabama +29 locations
Conditions: Breast Cancer
Register for Updates
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
NCT01964430
Completed
The purpose of this study is to compare whether there is a delay or prevention of recurrence or death in participants with surgically removed pancreatic cancer who then take nab-Paclitaxel in combination with gemcitabine compared to those who take gemcitabine alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2023
Locations: Local Institution - 043, Scottsdale, Arizona +340 locations
Conditions: Pancreatic Neoplasms, Digestive System Neoplasms, Neoplasms by Site, Neoplasms, Endocrine Gland Neoplasms, Pancreatic Diseases, Digestive System Diseases, Endocrine System Diseases, Gemcitabine, Antimetabolites, Antineoplastic
Register for Updates